Registry-Based Surveillance of Severe Acute Respiratory Infections in Norway During 2021-2024.

Seppälä E, Bøås H, Dahl J, Stålcrantz J, Stecher M, Tønnessen R, Rø GØI, Kløvstad H, Paulsen TH

Influenza Other Respir Viruses 19 (2) e70080 [2025-02-00; online 2025-02-14]

In 2021, the Norwegian Institute of Public Health established temporary registry-based surveillance of severe acute respiratory infections (SARI). We aimed to describe the surveillance system and evaluate selected attributes to inform the establishment of a permanent SARI surveillance system. SARI cases were defined using ICD-10 discharge codes from national health and administrative registries, including codes for acute upper or lower respiratory infection (URI and LRI), COVID-19, acute respiratory distress syndrome, pertussis or otitis media. Data from polymerase chain reaction (PCR) analyses were available for 10 respiratory pathogens including SARS-CoV-2, influenza virus and respiratory syncytial virus (RSV). We included data from 28 September 2020 to 31 March 2024 and calculated the following parameters: the proportion of cases tested for SARS-CoV-2, influenza virus and/or RSV; time between admission and registration of a SARI-related ICD-10 code; and proportion of cases with URI, LRI and COVID-19. We identified 214,730 SARI cases, of whom 82%, 73% and 53% were tested for SARS-CoV-2, influenza virus and RSV. Case peaks were predominantly driven by one or a combination of these pathogens. Median time between admission and a registered SARI diagnostic code was 5 (lower-upper quartile 3-10) days. Nowcasting and alternative case definitions for SARI with COVID-19, influenza and RSV improved the timeliness. The ICD-10 codes for LRIs and COVID-19 captured only ~55% of the cases in the age group of 0-29 years compared to the routine case definition, where URIs were included. Registry-based SARI surveillance provides timely data for handling epidemics of respiratory infections in Norway. We recommend establishing a permanent SARI surveillance system.

PubMed 39950571

DOI 10.1111/irv.70080

Crossref 10.1111/irv.70080

pmc: PMC11826439


Publications 9.5.1